Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and PerspectivesFabiana Alves, Jorge Alvar, Eduard E. Zijlstra et al.|Clinical Microbiology Reviews|2018Cited by 218
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in BangladeshRidwanur Rahman, Bhawna Sharma, Vishal Goyal et al.|PLoS neglected tropical diseases|2017Cited by 78
AmBisome Monotherapy and Combination AmBisome–Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 TrialSakib Burza, Krishna Pandey, Raman Mahajan et al.|Clinical Infectious Diseases|2022Cited by 53
Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, IndiaVishal Goyal, Fabiana Alves, Vidya Nand Rabi Das et al.|PLoS neglected tropical diseases|2020Cited by 37
Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, IndiaVishal Goyal, Jorge Alvar, Raman Mahajan et al.|PLoS neglected tropical diseases|2018Cited by 25